2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
40
Triple Negative Breast Neoplasms
34
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Transitional Cell
10
Urinary Bladder Neoplasms
9
Neoplasm Metastasis
8
Lung Neoplasms
5
Brain Neoplasms
5
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Glioblastoma
3
Uterine Cervical Neoplasms
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Urothelial Bladder Carcinoma
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Interventions
Iodine-131
21
lenvatinib
17
Magnetic Resonance Spectroscopy
17
trametinib
13
Sorafenib
13
Thyrotropin Alfa
12
pembrolizumab
11
dabrafenib
11
Thyroidectomy
10
Surgical Procedures, Operative
10
Thyroxine
9
Paclitaxel
9
vandetanib
8
selpercatinib
8
Sunitinib
7
Nivolumab
7
Fluorodeoxyglucose F18
7
cabozantinib
6
anlotinib
6
Everolimus
6
Biopsy
6
pazopanib
5
Vemurafenib
5
Triiodothyronine
5
Specimen Handling
5
Saline Solution
5
Radiotherapy
5
Radiofrequency Ablation
5
Iodine-124
5
Cyclophosphamide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
sacituzumab govitecan
×
Clear all
NCT06923826
2025-07-25
TROP2
National University Hospital, Singapore
Phase 2
Recruiting
32 enrolled